Patents by Inventor Becky A. Durtschi

Becky A. Durtschi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion proteins comprising carriers that can induce a dual immune response
    Patent number: 6911206
    Abstract: The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a peptide endogenously synthesized within the vertebrate, the activity of which peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate; connected to (b) a second proteinaceous portion analogous to all or part of an immunogen from a pathogen, which pathogen is capable of pathogenically infecting the vertebrate; the portion (b) causing the vertebrate's immune system to recognize the portion (a) and produce a response that: (i) inhibits the activity of the peptide endogenously synthesized within the vertebrate; and (ii) protects the vertebrate from infection by the pathogen, when the vertebrate is vaccinated with an effective amount of the fusion protein.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: June 28, 2005
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Manuel Campos, Terecita D. Yule, Serge Martinod, Becky A. Durtschi
  • Fusion proteins comprising carriers that can induce a dual immune response
    Publication number: 20050095258
    Abstract: The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a peptide endogenously synthesized within the vertebrate, the activity of which peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate; connected to (b) a second proteinaceous portion analogous to all or part of an immunogen from a pathogen, which pathogen is capable of pathogenically infecting the vertebrate; the portion (b) causing the vertebrate's immune system to recognize the portion (a) and produce a response that: (i) inhibits the activity of the peptide endogenously synthesized within the vertebrate; and (ii) protects the vertebrate from infection by the pathogen, when the vertebrate is vaccinated with an effective amount of the fusion protein.
    Type: Application
    Filed: November 29, 2004
    Publication date: May 5, 2005
    Inventors: Manuel Campos, Terecita Yule, Serge Martinod, Becky Durtschi
  • Polynucleotide molecules encoding Neospora proteins
    Publication number: 20030180785
    Abstract: The present invention provides isolated polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1 and MAG1 proteins from Neospora caninum, as well as recombinant vectors, transformed host cells, and recombinantly-expressed proteins. The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the bidirectional GRA1/MAG1 promoter of N. caninum. The present invention further provides genetic constructs based on the polynucleotide molecules of the present invention that are useful in preparing modified strains of Neospora cells for use in vaccines against neosporosis.
    Type: Application
    Filed: April 21, 2003
    Publication date: September 25, 2003
    Applicants: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: B. Rajendra Krishnan, Rebecca Madura, Christine Yoder, Becky Durtschi, David A. Brake
  • Polynucleotide molecules encoding neospora proteins
    Patent number: 6600027
    Abstract: The present invention provides isolated polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1 and MAG1 proteins from Neospora caninum, as well as recombinant vectors, transformed host cells, and recombinantly-expressed proteins. The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the bidirectional GRA1IMAGI promoter of N. caninum. The present invention further provides genetic constructs based on the polynucleotide molecules of the present invention that are useful in preparing modified strains of Neospora cells for use in vaccines against neosporosis.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: July 29, 2003
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: B. Rajendra Krishnan, Rebecca Madura, Christine Yoder, Becky Durtschi, David A. Brake
  • DNA encoding neospora dihydrofolate reductase-thymidylate synthase
    Patent number: 6436410
    Abstract: The present invention provides isolated polynucleotide molecules comprising a nucleotide sequence encoding the DHFR-TS protein of Neospora which polynucleotide molecules are useful in preparing modified live vaccines against neosporosis, and as diagnostic reagents. The present invention further provides cloning and expression vectors, transformed host cells, substantially purified DHFR-TS proteins and peptide fragments, genetic constructs useful for targeted gene deletion, and vaccine compositions.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: August 20, 2002
    Assignee: Pfizer, Inc.
    Inventors: B. Rajendra Krishnan, S. Christine Yoder, Becky A. Durtschi